Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 18, 2020 2:39pm
191 Views
Post# 32141634

RE:CIDY vs THTX..

RE:CIDY vs THTX..Don't let some tax loss selling get you to down as it is temporary. And 2021 could be an absolutely outstanding year for THTX. If you been in the stock a while like many of us, the worst thing you could do now would be to let the trend over the last week get to you too much, causing you to abandon the ship, and then miss out on what 2021 likely holds for shareholders. NASH alone is a very big deal but the cancer situation could be stunning. 

Adonis wrote: why the management of CYDY succeeded in giving a capitalization of 3 billion to its company, and that of THTX failed yet THTX has better baggage ..! ?? change the name of the company or sell it to a big pharma you are unable to go it alone, it's amazing what happens in MS, even if we don't take into consideration cancer and NASH just with trogarzo and egrifta we are entitled to a few green days, right? The SP will back to 1.5$ soon..


<< Previous
Bullboard Posts
Next >>